Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)

被引:26
作者
Saraswat, Aishwarya L. [1 ]
Vartak, Richa [1 ]
Hegazy, Rehab [1 ,2 ]
Patel, Akanksha [1 ]
Patel, Ketan [1 ]
机构
[1] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA
[2] Natl Res Ctr, Pharmacol Dept, Med Div, Giza, Egypt
基金
美国国家卫生研究院;
关键词
PROTAC; Nanoformulation; Protein degradation; Targeted therapy; Solubility enhancement; Drug permeation; PROTEIN-DEGRADATION; ABSORPTION; UBIQUITINATION; MOLECULES; CANCER;
D O I
10.1016/j.drudis.2022.103387
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteolysis targeting chimeras (PROTACs) have been extensively explored for targeted proteasomal degradation of disease-related proteins with enormous potential in the treatment of intractable diseases. However, PROTACs are poorly soluble and permeable bulky molecules facing several bioavailability challenges irrespective of the route of administration. Our review lays out crucial challenges in the delivery of target protein degraders and nanoformulation approaches to overcome physicochemical and biological hurdles that can aid in transporting these target-protein degraders to the disease site. We have elaborated on the current formulation approaches and further highlighted the prospective delivery strategies that could be probed for disease-specific targeted delivery of PROTACs.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 63 条
  • [1] Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
    Alex, Alexander
    Millan, David S.
    Perez, Manuel
    Wakenhut, Florian
    Whitlock, Gavin A.
    [J]. MEDCHEMCOMM, 2011, 2 (07) : 669 - 674
  • [2] Advances in Oral Drug Delivery
    Alqahtani, Mohammed S.
    Kazi, Mohsin
    Alsenaidy, Mohammad A.
    Ahmad, Muhammad Z.
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
    An, Sainan
    Fu, Liwu
    [J]. EBIOMEDICINE, 2018, 36 : 553 - 562
  • [4] Non-invasive delivery strategies for biologics
    Anselmo, Aaron C.
    Gokarn, Yatin
    Mitragotri, Samir
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (01) : 19 - 40
  • [5] Cancer active targeting by nanoparticles: a comprehensive review of literature
    Bazak, Remon
    Houri, Mohamad
    El Achy, Samar
    Kamel, Serag
    Refaat, Tamer
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) : 769 - 784
  • [6] PROTAC targeted protein degraders: the past is prologue
    Bekes, Miklos
    Langley, David R.
    Crews, Craig M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) : 181 - 200
  • [7] From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
    Cecchini, Carlotta
    Pannilunghi, Sara
    Tardy, Sebastien
    Scapozza, Leonardo
    [J]. FRONTIERS IN CHEMISTRY, 2021, 9
  • [8] Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
    Chakraborty, Chiranjib
    Sharma, Ashish Ranjan
    Sharma, Garima
    Doss, C. George Priya
    Lee, Sang-Soo
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 8 : 132 - 143
  • [9] Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles
    Chen, Jinjin
    Qiu, Min
    Ma, Feihe
    Yang, Liu
    Glass, Zachary
    Xu, Qiaobing
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 330 : 1244 - 1249
  • [10] Therapeutic efficacy of nanoparticles and routes of administration
    Chenthamara, Dhrisya
    Subramaniam, Sadhasivam
    Ramakrishnan, Sankar Ganesh
    Krishnaswamy, Swaminathan
    Essa, Musthafa Mohamed
    Lin, Feng-Huei
    Qoronfleh, M. Walid
    [J]. BIOMATERIALS RESEARCH, 2019, 23 (01)